{"id":32355,"date":"2025-07-30T08:41:23","date_gmt":"2025-07-30T08:41:23","guid":{"rendered":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-2\/"},"modified":"2025-07-30T08:41:23","modified_gmt":"2025-07-30T08:41:23","slug":"estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/","title":{"rendered":"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864)"},"content":{"rendered":"<p>MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; Roche Registration Limited<\/p>","protected":false},"excerpt":{"rendered":"<p>MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; Roche Registration Limited<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-32355","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864) - Ibima\" \/>\n<meta property=\"og:description\" content=\"MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; Roche Registration Limited\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:41:23+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864)\",\"datePublished\":\"2025-07-30T08:41:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/\"},\"wordCount\":56,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/\",\"name\":\"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:41:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/","og_locale":"en_GB","og_type":"article","og_title":"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864) - Ibima","og_description":"MARIA VANESA GUTIERREZ CALDERON &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; Roche Registration Limited","og_url":"https:\/\/ibima.eu\/en\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:41:23+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864)","datePublished":"2025-07-30T08:41:23+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/"},"wordCount":56,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/","url":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/","name":"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:41:23+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-aleatorizado-abierto-en-fase-iii-de-pralsetinib-frente-al-tratamiento-de-referencia-para-el-tratamiento-de-primera-linea-del-cancer-de-pulmon-metastatico-no-microcitico-metastatico-positivo-p\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio aleatorizado, abierto en Fase III de Pralsetinib frente al tratamiento de referencia para el tratamiento de primera l\u00ednea del c\u00e1ncer de pulm\u00f3n metast\u00e1tico no microc\u00edtico metast\u00e1tico positivo para el gen de fusi\u00f3n RET (BO42864)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=32355"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32355\/revisions"}],"predecessor-version":[{"id":55381,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32355\/revisions\/55381"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=32355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=32355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=32355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}